11 results about "Ocular Infections" patented technology

The invention discloses a pathogen detection primer group, a kit and application in eye infection pathogen detection, the detection primer group comprises 162 pairs of primers for 54 pathogenic microorganisms, the interference competition among the primers is small, the 54 pathogenic microorganisms can be detected at the same time by randomly selecting one pair of primers for each pathogenic microorganism, and the detection efficiency is high. When all 162 pairs of primers are selected, the sensitivity and specificity of species identification can be improved, the specific and high-sensitivity detection of bacteria, fungi, viruses, parasites and accurately identified species can be met, and the requirements of clinical accurate diagnosis are met.

Methods of detection and identification of microbial eye infections by molecular analysis of nucleic acid in tear samples are provided. 16S rDNA is amplified by PCR directly from tear samples without extracting DNA and the amplification products are sequenced by nanopore sequencing so that the microbes can be identified.

The present invention relates to a novel pharmaceutical composition suitable for ophthalmic use comprising antibiotic and process to prepare the same. More particularly, the present invention relates to a pharmaceutical gel composition comprising aminoglycoside antibiotics such as plazomicin or its pharmaceutically acceptable salts thereof for the treatment of ocular infections.

The invention discloses a bacteriostasis-related protein as well as a biological material and application thereof. The technical problem to be solved by the invention is how to inhibit bacteria. The invention specifically discloses application of the G enzyme. The application is any one of the following items: A1) application in preparation of a product for promoting wound healing; a2) in preparation of a product for promoting healing of infectious wounds; a3) in preparation of a product for promoting and / or assisting in promoting wound healing; a4) in preparation of a product for enhancing the antibacterial and / or bactericidal ability of antibiotics; a5) application in preparation of a product for enhancing the ability of antibiotics to treat or / and prevent eye infection; a6) in improving the cell activity and / or preparing a product for improving the cell activity. The G enzyme is any one of the following items: B1) the amino acid sequence is a protein of a sequence 1 or 31-442 sites of the sequence 1; b2) a protein which is obtained by substitution and / or deletion and / or addition of amino acid residues of the protein B1), has 80% or more of identity with the protein B1) and has the same activity with the protein B1); b3), a fusion protein obtained by connecting the N terminal or / and the C terminal of B1) or B2) with a protein tag. The G enzyme disclosed by the invention has an obvious antibacterial effect when being used for gram-negative bacteria, and can be used for industrial production.

This invention, entitled "Primer and Probe Composition, Kit, and Application for Detecting Ocular Infectious Pathogens," belongs to the field of molecular biology detection technology. The technical problems it aims to solve are cumbersome single-detection procedures, cross-reactivity in multiple detections, and insufficient sensitivity. The key technical solution is to provide a primer and probe composition for detecting ocular infectious pathogens. This composition includes primers and probes for detecting the CMV UL123 gene, the AdV Hexon gene, and the EBV EBNA-1 gene, along with internal quality control primers and probes, and employs four different fluorescent labels. This invention also provides a kit containing the above primer and probe composition. The kit enables simultaneous qualitative and quantitative detection of three pathogens: CMV, AdV, and EBV, with high accuracy and sensitivity, suitable for early diagnosis, disease monitoring, and prognostic assessment of ocular infections.

The present disclosure relates to a method to reduce virulence of Tsukamurella comprising decreasing the expression of the mycolyltransferase C (‘tmytC”) gene. Also disclosed is a pharmaceutical composition and method of prevention and treatment of infection by inhibition of tmytC.

This invention discloses an injectable AuPd-Fe single-atom nanozyme composite drug-derived antibacterial hydrogel, its preparation method, and its applications, belonging to the field of biomedical nanomaterials technology. This invention uses an iron-based single-atom nanozyme with an irregular octahedral carbon framework structure as the core catalytic carrier, and in situ loads ultra-small AuPd alloy nanoparticles onto its surface to obtain the AuPd-Fe single-atom nanozyme. Then, using the AuPd-Fe single-atom nanozyme as the active center and oleanolic acid drug-derived hydrogel as the delivery carrier, the AuPd-Fe single-atom nanozyme is uniformly dispersed in the three-dimensional network of the OA hydrogel through physical embedding and hydrogen bonding, resulting in the injectable AuPd-Fe single-atom nanozyme composite drug-derived antibacterial hydrogel. The provided antibacterial hydrogel exhibits excellent ocular surface biocompatibility, no significant corneal toxicity, and no systemic organ damage. It also shows significant clinical application potential for blinding ocular infections such as drug-resistant bacterial keratitis and corneal ulcers.

The present invention provides a novel pharmaceutical composition of polymyxin B / trimethoprim and rifampicin, as well as a preparation method and topical ocular application thereof (e.g., treatment of ocular infections).

The invention relates to nitric oxide-generating compositions, kits and combinations for the treatment, amelioration or prevention of ophthalmic infectious or inflammatory diseases or disorders, or infectious or inflammatory diseases or disorders associated with an external body orifice of a subject and / or infectious or inflammatory diseases or disorders of an internal cavity immediately adjacent to the external orifice of a subject provided that the infectious disease or disorder is not a urinary tract infection in a human subject, and methods of treating, ameliorating or preventing such diseases or disorders with the compositions, kits and combinations.

This invention, entitled "A Primer-Probe Combination for Simultaneous Detection of AMB, VZV, and HSV-1, and its Detection Method, Application, and Product," belongs to the field of molecular biology detection technology. The technical problem it aims to solve is that existing ocular infection detection technologies cannot simultaneously detect AMB, VZV, and HSV-1 in a single tube, or only cover the virus and miss AMB, or require multiple tubes, have unclear identification, insufficient sensitivity, and are difficult to adapt to small ocular samples, failing to meet the needs of rapid and accurate clinical diagnosis. The key technical solution is to provide specific primers and probes targeting the 18S rRNA gene of AMB, the ORF62 gene of VZV, and the UL30 gene of HSV-1, combined with internal quality control primers and probes, using four different fluorescent labels to establish a single-tube multiplex real-time fluorescent PCR detection method, and preparing a matching kit to achieve simultaneous detection and identification of the three pathogens. This invention features high sensitivity, specificity, and strong anti-interference ability.

Methods and pharmaceutical compositions for delivering a therapeutic agent, treating a neovascularization disorder, and treating an ocular infection include make use of a compound that includes an elastin-like polypeptide (ELP) coupled to a therapeutic agent, wherein the ELP comprises at least one repeat of the amino acid sequence VPGXG (SEQ ID NO: 1), and where the composition is suitable for ocular administration.